IGC Pharma annual total debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
IGC Pharma Total Debt Growth & History (IGC)
IGC Pharma's total debt was $145,000 for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | $145,000 | — | — |
| 2025 · Mar 31 | 2025-03-31 | $240,000 | −$108,000 | −31.03% |
| 2024 | 2024-03-31 | $348,000 | −$136,000 | −28.10% |
| 2023 | 2023-03-31 | $484,000 | −$127,000 | −20.79% |
| 2022 | 2022-03-31 | $611,000 | −$464,000 | −43.16% |
| 2021 | 2021-03-31 | $1.1M | $451,000 | +72.28% |
| 2020 | 2020-03-31 | $624,000 | $574,000 | +1148.00% |
| 2019 | 2019-03-31 | $50,000 | $50,000 | — |
| 2018 | 2018-03-31 | $0 | −$452,080 | — |
| 2017 | 2017-03-31 | $452,080 | −$377,149 | −45.48% |
| 2016 | 2016-03-31 | $829,229 | −$775,031 | −48.31% |
| 2015 | 2015-03-31 | $1.6M | $1.6M | — |
| 2014 | 2014-03-31 | $0 | $0 | — |
| 2013 | 2013-03-31 | $0 | $0 | — |
| 2012 | 2012-03-31 | $0 | −$901,343 | — |
| 2011 | 2011-03-31 | $901,343 | — | — |
IGC Pharma quarterly total debt
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | $0 | −$205,000 | — |
| Q1 2026 · Mar 31 | 2026-03-31 | $9,000 | −$231,000 | −96.25% |
| Q4 2025 · Dec 31 | 2025-12-31 | $145,000 | −$128,000 | −46.89% |
| Q2 2026 · Sep 30 | 2025-09-30 | $150,000 | −$157,000 | −51.14% |
| Q1 2026 · Jun 30 | 2025-06-30 | $205,000 | −$136,000 | −39.88% |
| Q4 2025 · Mar 31 | 2025-03-31 | $240,000 | −$108,000 | −31.03% |
| Q3 2025 | 2024-12-31 | $273,000 | −$107,000 | −28.16% |
| Q2 2025 | 2024-09-30 | $307,000 | −$111,000 | −26.56% |
| Q1 2025 | 2024-06-30 | $341,000 | −$110,000 | −24.39% |
| Q4 2024 | 2024-03-31 | $348,000 | −$136,000 | −28.10% |
| Q3 2024 | 2023-12-31 | $380,000 | −$135,000 | −26.21% |
| Q2 2024 | 2023-09-30 | $418,000 | −$130,000 | −23.72% |
| Q1 2024 | 2023-06-30 | $451,000 | −$129,000 | −22.24% |
| Q4 2023 | 2023-03-31 | $484,000 | −$127,000 | −20.79% |
| Q3 2023 | 2022-12-31 | $515,000 | −$127,000 | −19.78% |
| Q2 2023 | 2022-09-30 | $548,000 | −$122,000 | −18.21% |
| Q1 2023 | 2022-06-30 | $580,000 | −$117,000 | −16.79% |
| Q4 2022 | 2022-03-31 | $611,000 | −$464,000 | −43.16% |
| Q3 2022 | 2021-12-31 | $642,000 | −$454,000 | −41.42% |
| Q2 2022 | 2021-09-30 | $670,000 | −$446,000 | −39.96% |
| Q1 2022 | 2021-06-30 | $697,000 | −$488,000 | −41.18% |
| Q4 2021 | 2021-03-31 | $1.1M | $451,000 | +72.28% |
| Q3 2021 | 2020-12-31 | $1.1M | $1.0M | +2092.00% |
| Q2 2021 | 2020-09-30 | $1.1M | $1.1M | +2132.00% |
| Q1 2021 | 2020-06-30 | $1.2M | $1.1M | +2270.00% |
| Q4 2020 | 2020-03-31 | $624,000 | $574,000 | +1148.00% |
| Q3 2020 | 2019-12-31 | $50,000 | $50,000 | — |
| Q2 2020 | 2019-09-30 | $50,000 | $50,000 | — |
| Q1 2020 | 2019-06-30 | $50,000 | $50,000 | — |
| Q4 2019 | 2019-03-31 | $50,000 | $50,000 | — |
| Q3 2019 | 2018-12-31 | $0 | $0 | — |
| Q2 2019 | 2018-09-30 | $0 | −$350,794 | — |
| Q1 2019 | 2018-06-30 | $0 | −$175,991 | — |
| Q4 2018 | 2018-03-31 | $0 | −$452,080 | — |
| Q3 2018 | 2017-12-31 | $0 | −$446,000 | — |
| Q2 2018 | 2017-09-30 | $350,794 | −$302,959 | −46.34% |
| Q1 2018 | 2017-06-30 | $175,991 | −$432,873 | −71.10% |
| Q4 2017 | 2017-03-31 | $452,080 | −$377,149 | −45.48% |
| Q3 2017 | 2016-12-31 | $446,000 | −$740,568 | −62.41% |
| Q2 2017 | 2016-09-30 | $653,753 | −$151,806 | −18.84% |
| Q1 2017 | 2016-06-30 | $608,864 | −$977,150 | −61.61% |
| Q4 2016 | 2016-03-31 | $829,229 | −$775,031 | −48.31% |
| Q3 2016 | 2015-12-31 | $1.2M | $857,626 | +260.72% |
| Q2 2016 | 2015-09-30 | $805,559 | $454,386 | +129.39% |
| Q1 2016 | 2015-06-30 | $1.6M | $1.2M | +329.03% |
| Q4 2015 | 2015-03-31 | $1.6M | $1.6M | — |
| Q3 2015 | 2014-12-31 | $328,942 | $328,942 | — |
| Q2 2015 | 2014-09-30 | $351,173 | $351,173 | — |
| Q1 2015 | 2014-06-30 | $369,674 | $369,674 | — |
| Q4 2014 | 2014-03-31 | $0 | $0 | — |
| Q3 2014 | 2013-12-31 | $0 | −$4,557 | — |
| Q2 2014 | 2013-09-30 | $0 | −$177,300 | — |
| Q1 2014 | 2013-06-30 | $0 | −$200,761 | — |
| Q4 2013 | 2013-03-31 | $0 | $0 | — |
| Q3 2013 | 2012-12-31 | $4,557 | −$760,314 | −99.40% |
| Q2 2013 | 2012-09-30 | $177,300 | −$641,168 | −78.34% |
| Q1 2013 | 2012-06-30 | $200,761 | −$699,572 | −77.70% |
| Q4 2012 | 2012-03-31 | $0 | −$901,343 | — |
| Q3 2012 | 2011-12-31 | $764,871 | — | — |
| Q2 2012 | 2011-09-30 | $818,468 | — | — |
| Q1 2012 | 2011-06-30 | $900,333 | — | — |
| Q4 2011 | 2011-03-31 | $901,343 | — | — |
IGC Pharma total debt trends
Between the periods ended 2011-03-31 and 2025-12-31, IGC Pharma's total debt decreased from $901,343 to $145,000, a change of −$756,343. The latest reported quarter, Q2 2026 · Jun 30, shows $0.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IGC Pharma source filings ↗